Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
August 8, 2018

ADC Therapeutics doses first patient in Phase II trial of ADCT-402

ADC Therapeutics has dosed the first patient in a Phase II clinical trial to examine the efficacy and safety of ADCT-402 (loncastuximab tesirine) to treat patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

ADC Therapeutics has dosed the first patient in a Phase II clinical trial to examine the efficacy and safety of ADCT-402 (loncastuximab tesirine) to treat patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The trial, which will be conducted at various centres in the US and Europe, is expected to help ADC Therapeutics to submit a biologics licence application (BLA) to the US Food and Drug Administration (FDA).

Around 140 patients with relapsed or refractory DLBCL are expected to be enrolled in the multi-centre, open-label, single-arm trial.

The primary objective of the trial is the overall response rate (ORR) in patients treated with ADCT-402, as confirmed by central review.

“We anticipate reporting results from the Phase II trial in the third quarter of 2019 and are hopeful that the data will support our submission of a BLA to the FDA.”

The trial’s secondary objectives comprise evaluation of duration of response, complete response rate, relapse-free survival, progression-free survival and overall survival, as well as safety, pharmacokinetics and health-related quality of life.

ADC Therapeutics chief medical officer and clinical development senior vice-president of Jay Feingold said: “Our Phase I clinical trial of ADCT-402 in non-Hodgkin lymphoma showed significant activity in patients with DLBCL and an acceptable safety profile.”

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

“Unfortunately, there is no effective treatment for patients with multiple relapsed and refractory DLBCL, so we are excited about the potential to improve outcomes in these patients with ADCT-402 in a single-arm trial.

“We anticipate reporting results from the Phase II trial in the third quarter of 2019 and are hopeful that the data will support our submission of a BLA to the FDA.”

In addition, ADC Therapeutics intends to begin several combination studies with ADCT-402 in the fourth quarter of this year.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU